Ubiquitin is a small protein tag that cells attach to other proteins to change their fate, and the way ubiquitin molecules are linked together matters enormously. Whereas K48-linked chains typically condemn proteins to destruction by the proteasome, K63-linked chains serve a very different purpose: they orchestrate protein interactions, intracellular trafficking, and signaling activity without triggering degradation. UBE2N, also known as Ubc13, is the specialized E2 enzyme that builds these K63-linked chains, and its role in MASH had remained almost entirely unexplored until now.

The researchers began by examining liver tissue from both human patients and mouse models of MASH, and they found a consistent pattern: UBE2N was markedly downregulated in hepatocytes under metabolic stress. Digging into the mechanism, they identified THAP11 as a transcriptional repressor that binds the UBE2N promoter during disease progression, effectively silencing the enzyme as fatty acids accumulate. Single-nucleus RNA sequencing and digital spatial transcriptomics confirmed that this drop in UBE2N expression is specifically concentrated in hepatocytes rather than other liver cell types.

To establish causality, the team generated mice lacking Ube2n selectively in hepatocytes. When these animals were placed on a western diet, they developed dramatically worse MASH and liver fibrosis than their normal counterparts. Serum liver enzymes rose, inflammatory and fibrogenic genes were upregulated, and the livers showed extensive fat accumulation and scarring. Crucially, when the researchers overexpressed UBE2N in the liver, the pathological phenotypes reversed and hepatic homeostasis was largely restored, demonstrating that the enzyme is not merely a bystander but an active protector.

The mechanism underlying this protection turned out to involve two intimately connected processes: mitophagy and PANoptosis. Mitophagy is the cellular quality-control system that identifies damaged mitochondria and delivers them to lysosomes for degradation, preventing the release of inflammatory mitochondrial contents. PANoptosis, by contrast, is a recently defined form of inflammatory programmed cell death that combines features of pyroptosis, apoptosis, and necroptosis simultaneously, unleashing a potent inflammatory storm. The new study shows that when UBE2N is lost, mitophagy collapses and PANoptosis erupts, creating the destructive combination that drives MASH forward.

At the molecular level, the researchers traced how UBE2N keeps mitophagy running smoothly. Working with the PARKIN pathway, they found that UBE2N catalyzes K63-linked ubiquitination of p62, also known as SQSTM1, at a specific site, lysine 420. This modification acts as a trafficking signal, promoting the translocation of K63-tagged p62 into damaged mitochondria where it serves as an autophagy receptor, tethering the cargo to the autophagic machinery for clearance. In cells lacking UBE2N, this modification fails to occur, p62 fails to reach the mitochondria, and damaged organelles accumulate unchecked.

But the story has an unexpected twist. When p62 cannot reach mitochondria, it accumulates in the cytoplasm, and this cytoplasmic buildup has consequences of its own. The researchers found that cytoplasmic p62 aggregation drives hyperactivation of NRF2, a transcription factor normally considered protective against oxidative stress. While NRF2 activation is beneficial in moderation, the study demonstrates that excessive, sustained NRF2 signaling in this context actively promotes PANoptosis and worsens liver damage. This finding challenges the simplistic view of NRF2 as an unambiguously protective factor in liver disease.

To prove that p62 accumulation is truly the culprit, the team generated mice lacking both Ube2n and Sqstm1 in hepatocytes. Remarkably, this additional deletion substantially mitigated the severe liver pathology caused by Ube2n loss alone, confirming that the damaging effects of UBE2N deficiency flow largely through cytoplasmic p62 buildup. The result establishes p62 as a proof-of-concept therapeutic target: if its cytoplasmic accumulation can be prevented or its mitochondrial routing restored, the downstream cascade of NRF2 hyperactivation and PANoptosis might be interrupted.

The implications extend beyond basic biology. MASH currently affects hundreds of millions of people worldwide, and only recently did the first targeted therapy, the thyroid hormone receptor-beta agonist resmetirom, gain approval. The identification of UBE2N and the p62 trafficking pathway offers an entirely new axis for intervention, one that operates at the level of mitochondrial quality control rather than lipid metabolism alone. Hepatic targeting of Ube2n in the mouse models prevented western diet-induced MASH progression, suggesting that gene-based or small-molecule approaches aimed at restoring this pathway could be feasible.

There remain significant challenges before this biology can be translated into treatments. UBE2N participates in immune receptor signaling and skin homeostasis, so systemic manipulation carries risks of off-target effects, and the precise dose, timing, and delivery method for hepatic intervention would need careful optimization. Nonetheless, the study provides an unusually complete mechanistic arc, from a transcriptional repressor silencing a ubiquitin enzyme, through defective mitochondrial tagging and cytoplasmic protein aggregation, to inflammatory cell death and fibrosis, and it does so with consistent evidence from human tissue, mouse genetics, and cell biology. For a field desperate for new molecular handles on a growing epidemic, UBE2N and its p62-dependent pathway represent one of the most compelling new entries in years.

Subject of Research: Role of UBE2N-regulated p62 mitophagy and PANoptosis in metabolic dysfunction-associated steatohepatitis

Article Title: UBE2N deficiency contributes to MASH development via p62-regulated mitophagy and PANoptosis

Article References: UBE2N deficiency contributes to MASH development via p62-regulated mitophagy and PANoptosis. (n.d.). https://doi.org/10.1038/s42255-026-01590-0

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01590-0

Keywords: UBE2N, MASH, p62, SQSTM1, mitophagy, PANoptosis, K63-linked ubiquitination, PARKIN, NRF2, THAP11, liver fibrosis, Nature Metabolism

Mitophagy, the selective autophagic degradation of mitochondria, is a fundamentally protective process. By wrapping damaged organelles in autophagosomal membranes and delivering them to lysosomes for destruction, the cell prevents the accumulation of dysfunctional mitochondria that would otherwise poison it from within. In the liver, this process is particularly important because hepatocytes are continuously exposed to fatty acids, inflammatory cytokines and oxidative stress in conditions such as obesity and insulin resistance. Previous work has established that impaired mitochondrial homeostasis contributes to the initiation and progression of hepatic injury, and that defects in mitophagy are associated with the transition from simple steatosis to the inflammatory, fibrotic state that defines steatohepatitis. What has been missing is a clear mechanistic picture of the decision point at which a damaged mitochondrion is routed toward degradation rather than allowed to trigger cell death pathways.

Wang and colleagues addressed this question by focusing on ubiquitin signaling, the cellular language by which proteins are tagged for different fates. Ubiquitination involves the sequential action of activating enzymes, conjugating enzymes and ligases, and the identity of the ubiquitin chain, together with the substrate that carries it, encodes instructions that are read by autophagy receptors and other effector proteins. UBE2N, also known as Ubc13, is an E2 conjugating enzyme with a well-documented role in catalyzing the assembly of lysine 63-linked ubiquitin chains, a chain type classically associated with signaling rather than proteasomal degradation. Through its pairing with specialized E2 variant proteins, UBE2N builds K63-linked chains on substrate proteins that regulate inflammatory pathways, DNA damage responses and, as the new study demonstrates, autophagic cargo recognition.

The central discovery reported in the study is that UBE2N-mediated ubiquitination of p62, an autophagy receptor also known as sequestosome-1, acts as the switch between protective mitophagy and pathogenic cell death in hepatocytes. p62 is a multi-domain adaptor protein that simultaneously binds ubiquitin chains through its ubiquitin-associated domain and LC3, a core component of the autophagosomal membrane, through its LC3-interacting region. In doing so, p62 physically links ubiquitinated cargo, including damaged mitochondria, to the autophagic machinery. The canonical mitophagy pathway, which depends on the mitochondrial kinase PINK1 and the E3 ubiquitin ligase Parkin, works by ubiquitinating outer mitochondrial membrane proteins on depolarized mitochondria, after which receptors such as p62 help orchestrate the recruitment of phagophores. K63-linked chains generated by UBE2N had previously been implicated in autophagic clearance of protein aggregates and intracellular bacteria, but their role in mitochondrial quality control in the liver had not been defined.

By demonstrating that UBE2N directly modifies p62 with K63-linked ubiquitin chains, the study reveals an unexpected regulatory layer upstream of receptor-mediated cargo recognition. When UBE2N is active, ubiquitinated p62 is competent to engage damaged mitochondria and shepherd them into autophagosomes, preserving mitochondrial integrity and hepatocyte survival. When UBE2N activity is lost or suppressed, this routing fails: damaged mitochondria persist, their dysfunction amplifies, and the balance of cellular decision-making tips away from autophagic repair and toward cell death programs. In the context of MASH, where hepatocytes are chronically assaulted by lipotoxic stress and inflammatory signaling, this tipping point is the difference between adaptation and injury. The study’s framing of UBE2N as a molecular switch is therefore not merely metaphorical; it reflects a mechanistic bifurcation in which a single enzymatic activity determines the fate of both the organelle and the cell.

The pathological consequences of losing this switch were made evident in experimental models of metabolic dysfunction-associated steatohepatitis. MASH is characterized histologically by hepatic steatosis, lobular inflammation, hepatocyte ballooning and, in advanced stages, fibrosis. It is the progressive, inflammatory form of metabolic dysfunction-associated steatosis, formerly known as nonalcoholic fatty liver disease, and it affects a substantial and growing fraction of the global population in parallel with rising rates of obesity and type 2 diabetes. Current therapeutic options remain limited, and there is intense interest in identifying the intracellular quality-control pathways whose failure drives disease progression. The new findings place mitochondrial quality control, and specifically the ubiquitin code that governs it, at the center of that pathology, suggesting that defects in UBE2N-dependent signaling could contribute to why some patients progress from fatty liver to inflammatory, fibrotic disease while others do not.

Beyond the immediate findings, the study connects to a rich literature on mitophagy receptors and their regulation. p62 was first characterized as a scaffold in NF-kappaB signaling and later recognized as a prototypical selective autophagy receptor, with roles in the clearance of ubiquitinated protein aggregates, peroxisomes and mitochondria. The PINK1-Parkin pathway, whose discovery grew out of genetic studies of familial Parkinson’s disease, relies heavily on ubiquitin chain amplification on the mitochondrial surface, and adaptor proteins such as p62, NDP52 and OPTN translate that ubiquitin signal into autophagosome engagement. What Wang and colleagues add is the identification of the enzyme that licenses p62 itself, effectively placing UBE2N upstream of the receptor that all downstream mitophagy depends upon. This is conceptually significant because it suggests that modulating a single E2 enzyme could, in principle, tune the entire receptor-mediated mitophagy apparatus in hepatocytes.

The therapeutic implications are worth considering carefully. Pharmacological activation of mitophagy has long been proposed as a strategy for neurodegenerative disease, and the same logic applies to the liver, where boosting the clearance of dysfunctional mitochondria could interrupt the feed-forward loop of oxidative stress, inflammation and cell death that drives MASH progression. If UBE2N activity, or the K63-linked ubiquitination of p62 that it catalyzes, can be selectively enhanced, it may be possible to restore mitochondrial quality control in diseased livers without broadly suppressing inflammation or interfering with other ubiquitin-dependent processes. Conversely, the study serves as a caution: because UBE2N participates in innate immune signaling pathways, including the assembly of signaling complexes downstream of pattern-recognition receptors, any therapeutic manipulation would need to be calibrated to avoid unintended immunological consequences. The specificity of the p62-UBE2N interaction identified in the study may offer a route to such targeted intervention.

From a basic science perspective, the work also raises questions that will likely shape the field in the coming years. Which E3 ubiquitin ligase partners with UBE2N to decorate p62 with K63-linked chains? Is this modification reversible by deubiquitinating enzymes, and if so, do those enzymes represent additional nodes of regulation? How is the UBE2N-p62 axis coordinated with PINK1-Parkin activity at the mitochondrial surface, and does lipotoxic stress directly modulate UBE2N expression or localization in hepatocytes? Answering these questions will require the kind of integrated biochemical, cell biological and in vivo approach that the current study exemplifies, and the answers will determine how quickly the switch concept can be translated into clinical practice.

For now, the message of the new Nature Metabolism study is clear and consequential: hepatocyte survival in metabolic liver disease hinges on a ubiquitin-driven decision, and UBE2N sits at the fulcrum. By flipping that switch toward mitophagy, cells protect themselves; when the switch fails, the same mitochondria that once powered the cell become instruments of its destruction. As rates of MASH continue to climb worldwide, understanding and ultimately manipulating this switch may prove to be one of the more promising avenues for protecting the livers of millions of patients.

Subject of Research: The role of UBE2N-mediated ubiquitination of p62 in regulating mitophagy versus cell death in metabolic dysfunction-associated steatohepatitis (MASH).

Article Title: UBE2N flips the switch on for mitophagy and off for MASH

Article References: Madigan, E. D., Matos, S. L., & Jurczak, M. J. (2026). UBE2N flips the switch on for mitophagy and off for MASH. Nature Metabolism. https://doi.org/10.1038/s42255-026-01604-x

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01604-x

Keywords: UBE2N, mitophagy, MASH, p62, ubiquitination, hepatocytes, liver disease, mitochondria, autophagy, K63-linked ubiquitin chains, metabolic dysfunction-associated steatohepatitis, PINK1-Parkin